Published in:
01-12-2021 | Myelodysplastic Syndrome | Review
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Authors:
Li Xuan, Qifa Liu
Published in:
Journal of Hematology & Oncology
|
Issue 1/2021
Login to get access
Abstract
Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT.